MarginsXMarginsX
Home › Markets › Health Care › IOVA

Iovance Biotherapeutics Inc. (IOVA)

IOVA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.55
-2.71% on the day
Market cap
$3.5B
Mid cap
Revenue · 2025
$263.5M
+60.6% on 2024
Net income · 2025
-$391.0M
-148.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/0001104659-26-018899-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIOVA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001425205
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$263.5M
Net income-$391.0M
Operating income-$403.4M
Net margin-148.4%
Operating margin-153.1%
Revenue growth+60.6%
Cash$163.1M
Total assets$913.2M
P/E (computed)Net income was not positive
P/S (computed)13.3×

Warning signs

Cash runway
3.7 months
$57.9M cash at September 30, 2026
Share count, 1 year
+16.5%
2025-10-15 to 2026-10-27 · +80.8% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$57.9M cash; operating cash flow -$47.5M a quarter.Report 2026-09-30
Shares outstanding462,655,151 (2026-10-27); 396,967,970 a year earlier; 255,918,448 three years earlier.Cover page 2026-10-27
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$121.5M-$22.3M-$4.5M$57.9MNo debt tags$379.0M10-Q 2026-11-05
Q2 2026
2026-06-30
$99.3M-$47.3M-$60.8M$110.8MNo debt tags$325.0M10-Q 2026-08-06
Q1 2026
2026-03-31
$71.4M-$79.0M-$72.1M$196.5M$1.0M$285.6M10-Q 2026-05-07
Q4 2025
2025-12-31
$86.8M-$71.9M-$52.6M$163.1M$1.0M$263.5M10-K 2026-02-24
Q3 2025
2025-09-30
$67.5M-$91.3M-$78.7M$158.1M$1.0M$250.4M10-Q 2026-11-05
Q2 2025
2025-06-30
$60.0M-$111.7M-$67.4M$132.5M$1.0M$241.5M10-Q 2026-08-06
Q1 2025
2025-03-31
$49.3M-$116.2M-$103.7M$171.7M$1.0M$212.7M10-Q 2026-05-07
Q4 2024
2024-12-31
$73.7M-$78.6M-$73.3M$115.7MNo debt tags$164.1M10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-06-18
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.5%
1 month-46.5%
3 months+19.0%
Year to date+184.2%
1 year+222.0%
From 52-week high-47.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
RLAYRelay Therapeutics Inc.$17.27-4.53%$3.8B
TARSTarsus Pharmaceuticals Inc.$78.68-1.99%$3.9B
CRSPCRISPR Therapeutics AG Common Shares$40.37-4.43%$3.9B
ADMAADMA Biologics Inc$13.47-1.54%$3.0B
VCELVericel Corporation$57.48+0.91%$2.9B
DNLIDenali Therapeutics Inc.$18.08-3.52%$2.9B
ADPTAdaptive Biotechnologies Corporation$27.87-4.03%$4.5B
SRRKScholar Rock Holding Corporation$44.54+3.09%$5.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier